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Elevated levels of IL-10 in the microenvironment of human ovarian cancer and murine
models of ovarian cancer are well established and correlate with poor clinical progno-
sis. However, amongst a myriad of immunosuppressive factors, the actual contribution
of IL-10 to the ovarian tumor microenvironment, the mechanisms by which it acts, and
its possible functional redundancy are unknown. We previously demonstrated that elim-
ination of the myeloid-derived suppressor cell (MDSC) compartment within the ovarian
tumor ascites inhibited tumor progression and, intriguingly, signiﬁcantly decreased local
IL-10 levels. Here we identify a novel pathway in which the tumor-inﬁltrating MDSC are the
predominant producers of IL-10 and, importantly, require it to develop their immunosup-
pressive function in vivo. Importantly, we demonstrate that the role of IL-10 is critical, and
not redundant with other immunosuppressive molecules, to in vivo tumor progression:
blockade of the IL-10 signaling network results in alleviation of MDSC-mediated immuno-
suppression, altered T cell phenotype and activity, and improved survival. These studies
deﬁne IL-10 as a fundamental modulator of both MDSC andT cells within the ovarian tumor
microenvironment. Importantly, IL-10 signaling is shown to be necessary to the develop-
ment and maintenance of a permissive tumor microenvironment and represents a viable
target for anti-tumor strategies.
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INTRODUCTION
Ovarian cancer is characterized by a progressive peritoneal ascites
and a highly immunosuppressive tumor microenvironment inﬁl-
trated by massive numbers of leukocytes. Amongst a plethora of
known immunosuppressive factors within this tumor microenvi-
ronment, including arginase, TGF-β, and PD-L1, IL-10 has gen-
erated a great deal of interest. IL-10 has numerous suppressive
functions involved in dampening inﬂammatory responses of the
immune system, including inhibition of myeloid cell maturation
and reduction of expression of co-stimulatory molecules on den-
dritic cells (Moore et al., 2001). High levels of IL-10 are found in
the serum and ascites of ovarian cancer patients (Gotlieb et al.,
1992; Santin et al., 2001; Mustea et al., 2006, 2009; Giuntoli et al.,
2009; Nowak et al., 2010) and, importantly, IL-10 levels consis-
tently correlate with advanced disease and poor patient prognosis
in both ovarian cancer and other types of cancers (Lech-Maranda
et al., 2006;Mustea et al., 2006;Zeni et al., 2007;Nowak et al., 2010).
However, the exact roles IL-10 plays in the ovarian tumormicroen-
vironment and which of these directly contribute to the support of
tumorprogression are unknown.Additionally, given themultitude
of potentially redundant immunosuppressive factors present, how
the IL-10 signaling networks function and contribute within the
peritoneal ovarian tumor microenvironment is currently unclear.
Weandothers have shown that the substantialCD115+CD11b+
CD11c+ leukocyte compartment within the ovarian tumor envi-
ronment functions as myeloid-derived suppressor cells (MDSCs).
Of direct relevance, work from our group has shown that tar-
geted elimination of MDSCs resulted in a signiﬁcant decrease in
IL-10 within the ovarian tumor ascites and, concomitantly, inhib-
ited tumor progression (Bak et al., 2007; Peter et al., 2009). These
ﬁndings, combined with the aforementioned clinical correlations
between IL-10 and disease prognosis, led us to hypothesize that
IL-10 is a critical factor in ovarian tumor progression, that the
MDSCs within the tumor microenvironment are the predomi-
nant source of IL-10, and that the IL-10 network may provide a
viable therapeutic target.
Here we use the murine ID8 ovarian tumor model, the best
available transplantable model of ovarian cancer which recapit-
ulates critical characteristics of human epithelial ovarian cancer
(Roby et al., 2000). These features include a progressive accu-
mulation of ascites, elevated levels of IL-10, the recruitment of
massive numbers of leukocytes including a substantial population
of monocytic-like MDSC (MO-MDSC; Hart et al., 2009), and
allow for the generation of chimeric mice to directly test for dif-
ferences only attributable to speciﬁc genetic manipulations within
the same host and tumor. With this system we provide the ﬁrst
in vivo analysis of IL-10 signaling partners in the tumor and we
identify novel IL-10 pathways that deﬁne a critical role for IL-10
in tumor progression. These studies identify the CD11b+CD11c+
MDSCs as the predominant IL-10-producing cells in the ovar-
ian tumor microenvironment and, importantly, with the use of
mixed chimeric mice, we demonstrate that IL-10 directly and
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independently alters both MDSC and T cell phenotype and func-
tion. Moreover, we demonstrate that inhibition of the IL-10 sig-
naling network results in dramatically reduced tumor burden and
enhanced survival through a mechanism requiring T cells. These
studies identify a critical and non-redundant role for IL-10 in the
development and maintenance of a hospitable microenvironment
for the progression of ovarian tumors, and speciﬁcally identify IL-
10 signaling as a target for efﬁcacious therapeutic strategies against
the MDSCs that are known to potently inhibit the efﬁcacy of other
treatment modalities.
MATERIALS AND METHODS
REAGENTS
Female C57Bl/6 mice were purchased from the National Cancer
Institute (Fredricksburg, MD, USA). This study was carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Insti-
tutes of Health. The protocol was approved by the Dartmouth
IACUC Committee (Permit Number: A3259-01). No surgery was
performed, and all efforts were made to minimize suffering. IL-
10Rα−/− (Friedline et al., 2009) and IL-10 reportermice (Maynard
et al., 2007) were obtained from the Kang (UMASS – Worces-
ter) and Weaver (UAB) labs, respectively. MAFIA mice (Burnett
et al.,2004),under agreementwithARIADPharmaceuticals (Cam-
bridge, MA, USA), and TCRα mice were purchased from Jack-
son Laboratories (Bar Harbor, ME, USA). FOXP3-reporter mice
(Fontenot et al., 2003) were used in collaboration with Dr. Mary
Jo Turk at Dartmouth. All animal experiments were approved by
the Dartmouth Medical School Institutional Animal Care and Use
Committee. ID8 cells (Roby et al., 2000) transduced with Vegf-A
andDefb29 (referred to as ID8within thismanuscript) weremain-
tained as previously described (Conejo-Garcia et al., 2004). Anti-
mouse Fc Block, Phosﬂow phospho-STAT3 (pY705), Rat IgG1
isotype control, and anti-CD62L (MEL-14) were purchased from
BDBiosciences (San Jose,CA,USA); anti-mouseCD3 (145-2C11),
Gr-1 (RB6-8C5), CD45 (30-F11), CD11b (M1/70), CD8 (53–6.7),
CD4 (L3T4), MHC-II (M5/114.15.2), and CD45.1 (A20) anti-
bodies from eBioscience (San Diego, CA, USA); and anti-mouse
Thy1.1 (OX-7), CD11c (N418), and IFN-γ (XMG1.2) antibod-
ies from Biolegend (San Diego, CA, USA). IL-10 was assessed
using murine DuoSet ELISAs (R&D Systems, Minneapolis, MN,
USA). Anti-mouse STAT3 (79D7) and anti-phospho-STAT3
(3E2) were purchased from Cell Signaling Technology (Danvers,
MA, USA).
TUMORS AND LEUKOCYTE ISOLATION
As indicated, ascites and blood were harvested from mice; red
blood cells were removed using ACK lysis buffer (0.15 M NH4Cl,
1.0 mM KHCO3, 0.1 mM EDTA). Cells were resuspended in 0.5%
BSA in PBS, or media, for further analysis or sorting. Cells
were isolated using human or mouse anti-CD11b microbeads
or mouse anti-Ly6G microbead kit (Miltenyi Biotec, Auburn,
CA, USA). Immunosuppression assays using isolated cell pop-
ulations from tumor-bearing mice were performed by our pre-
viously described methodology (Bak et al., 2008) and analyzed
for IFN-γ production by ELISA (R&D Systems, Minneapolis,
MN, USA).
FACS ANALYSES
Cells were pre-incubated with Fc-blocking antibody (clone 2.4G2)
prior to antibody staining. Flow cytometry and cell sorting was
done on the Accuri C6 and FACS Aria, and analyzed using CFlow
and FlowJo 8.8.2 software. Phospho-STAT3 staining was per-
formed by stimulating 106 cells with 100 ng/ml recombinant IL-10
(R&D Systems, Minneapolis, MN, USA) for 10 min at 37˚C. Cells
were ﬁxed with pre-warmed 4% paraformaldehyde, and perme-
abilized in ice cold methanol for 60 min prior to staining. Intracel-
lular IFN-γ staining was performed on splenocytes in 10 mg/ml
brefeldin A in complete medium at 37˚C for 5 h in the absence
or presence of 1 μg/ml anti-CD3 stimulation. Cells were stained
with anti-CD8, ﬁxed with paraformaldehyde, and permeabilized
with saponin before staining with APC-conjugated anti-IFN-γ.
CD62L analyses was performed on bead-selected CD8 splenocytes
cultured in the presence or not of 10 ng/ml of IL-10 for 72 h.
LUMINEX ANALYSIS
Centrifuged supernatants of 4 ml PBS peritoneal lavages were ana-
lyzed in the Norris Cotton Cancer Center Immune Monitoring
Laboratoryusing themouse 12-plex cytokinepanel (Bio-Rad,Her-
cules,CA,USA).Cytokine concentrationswere calculated as lavage
dilutions from each mouse based on a 250-μl peritoneal volume
for mice with no ascites, and the recovered volume for mice with
ascites. Samples that were below the level of Luminex detection
were set as the minimum detectable concentration.
WESTERN BLOT
Phospho-STAT3 western was performed on one million plated
Ly6G or CD11b selected Ly6G-depleted cells treated with 10 ng/ml
of IL-10 for 30 min, spun down, and resuspended in sample
buffer with beta-mercaptoethanol, heated for 5 min at 90˚C,
then run on a 12% SDS-PAGE gel. After transfer to a PVDF
membrane and blocking, membranes were incubated overnight
with primary antibody, washed, blocked, and incubated with an
HRP-secondary antibody. Bands were then detected with ECL
Plus Western Blotting Detection Reagent (Amersham Biosciences,
Buckinghamshire, UK).
CHIMERIC MICE
For chimeric mouse studies, C57Bl/6 and Ly5.1 IL-10R−/− bone
marrow was collected from femurs, the red blood cells lysed, and
washed. For the 20:80 ratio mixed bone marrow chimeras, IL-
10R knockout and TCRα knockout bone marrow was mixed at
the appropriate ratio. Mixed bone marrow was injected intra-
venously by periorbital injection into previously irradiated (1000
rads) naïve C57Bl/6 recipients.
ANTIBODY TREATMENT AND SURVIVAL
Mice were injected with ID8 tumor cells and treated with 100μg
of anti-IL-10 receptor antibody (clone 1b1.3A; BioXCell, West
Lebanon, NH, USA), PBS, or Rat IgG control antibody (Sigma,
St. Louis, MO, USA). Mice were sacriﬁced at the indicated times
following the treatment regimen, or monitored for survival. For
depletion experiments mice were injected once a week with anti-
CD8 monoclonal antibody (clone 2.43), generously provided
by Dr. Mary Jo Turk (Dartmouth Medical School, Lebanon,
NH, USA).
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RESULTS
MYELOID CELLS ARE THE PREDOMINANT PRODUCERS OF IL-10 IN THE
ASCITES OF OVARIAN TUMOR-BEARING MICE
A number of studies have reported high levels of IL-10 in the ovar-
ian cancer tumor microenvironment (Gotlieb et al., 1992; Murray,
2006; Mustea et al., 2009). To elucidate the role of IL-10 within
the ovarian tumor microenvironment, we analyzed the origin of
IL-10 in the ascites of tumor-bearing mice. Compared to cultured
CD11b+ cells isolated from the ascites, which secrete substantial
amounts of IL-10 into the supernatant, equivalent numbers of
ID8 tumor cells secrete undetectable levels of IL-10 as measured
by ELISA (Figure 1A). This is consistent with analyses showing
human ovarian tumor cell production of IL-10 to be limited (Nash
et al., 1998; Berger et al., 2001; Carr et al., 2008).
To identify cellular sources of IL-10 in the tumor microen-
vironment we used 10BiT reporter mice (Maynard et al., 2007),
which have the Thy1.1 antigen driven under control of the IL-10
promoter (Maynard et al., 2007). Compared to naïve mice, tumor-
bearing reporter mice exhibited a substantial portion of cells that
were positive for Thy1.1 in the peritoneum (Figure 1B). Notably,
the CD11b+ compartment in the ascites, which we have previ-
ously identiﬁed as functional MDSC (Bak et al., 2008; Hart et al.,
2009), not only robustly expressed the reporter but also repre-
sented the vast majority of the cells that stained positive for the
reporter, and also make up the bulk of the total leukocyte inﬁl-
trate (Figures 1C,D). Both CD4- and CD8-positive cells showed
limited expression of IL-10 in the tumor ascites (Figure 1B).
To further characterize the IL-10-producing population, since
CD11b-positive cells (Figure 1B) derive from both myeloid and
granulocytic lineages, we assessed IL-10 expression versus GR-1
expression. The IL-10 reporter revealed that IL-10 expression lies
in the GR-1-negative myeloid population (Figure 1E). Granulo-
cytes express both the Ly6C and Ly6G proteins (the components
of GR-1; Fleming et al., 1993), while myeloid cells do not express
Ly6G though Ly6C expression has been described on a population
of inﬂammatory monocytes (Geissmann et al., 2003). Therefore,
to further clarify the myeloid populations within the ascites we
independently assessed Ly6C and Ly6G expression on the CD11b
population and identiﬁed that the majority of the cells express
neither epitope, and those that do are primarily double posi-
tive (Figure 1F). There are a small percentage of cells that singly
express Ly6C,whichourprevious phenotypic analysis of the ascites
indicates are tumor-inﬁltrating monocytes (Hart et al., 2009).
Additionally,we found that theCD11b-positive cells expressed low
levels of F4/80 (Figure 1G). We also found a similar intermediate
expression pattern of CD11c on the CD11b-positive cells, with a
small percentage expressing higher levels of CD11c (Figure 1H).
This data indicates that the CD11b+ IL-10-producing cells in the
ascites are comprised of a myeloid population distinct from gran-
ulocytes, with phenotypic markers of monocytes, macrophages,
and dendritic cells.
T regulatory cells (Treg), another suppressive population
known to produce IL-10 in cancer (Liyanage et al., 2002;
Marshall et al., 2004; Kawaida et al., 2005; Kryczek et al.,
2006a; Mougiakakos et al., 2010), were comparatively assessed
with the use of MAFIA/FOXP3-GFP mice in which both the
CD115+ and FOXP3+ cells express GFP. MDSCs were identiﬁed
as CD115-GFP+CD11b+ cells, and Treg were identiﬁed as
CD45+CD4+FOXP3-GFP+ cells within the ascites. In contrast to
the substantial MDSC population, the Treg population was present
at extremely low frequencies (Figure 1I). In combination with the
relative minutia of CD4 T cells staining for the IL-10 reporter, this
indicates that the Treg population is not a predominant source of
IL-10 in these tumors.
LEUKOCYTES PREFERENTIALLY INDUCE STAT3 SIGNALING IN
RESPONSE TO IL-10 WITHIN THE TUMOR MICROENVIRONMENT
Having delineated the origin of IL-10, we next identiﬁed the
cellular network that responds to IL-10within the tumormicroen-
vironment. To directly identify IL-10 responsive cells in the
microenvironment, we analyzed STAT3 phosphorylation, a req-
uisite downstream signaling component from the IL-10 receptor
complex (Donnelly et al., 1999; Moore et al., 2001; Mosser and
Zhang, 2008). To do so we created chimeric mice by reconstitut-
ing lethally irradiated mice with equal amounts of bone marrow
from wild-type (WT) and congenic IL-10R−/− mice (Figure 2A);
reconstitution was subsequently assessed by staining with the
CD45.1 congenic marker (Figure 2B). ID8 ovarian tumors were
grown in these mice and the CD11b+ cells harvested from the
ascites. CD11b-positive wild-type cells, but not the IL-10 receptor
knockout cells derived from the same tumor-bearing mouse and
exposed to identical treatment, exhibited phospho-STAT3 stain-
ing after ex vivo IL-10 stimulation (Figure 2C). As a conﬁrmatory
and complimentary method,we assessed relative IL-10-stimulated
phosphorylation of STAT3 by Western analysis. Consistent with
our FACS results, CD11b-positive Ly6G-depleted cells, but not the
Ly6G-positive cells, exhibited IL-10-induced STAT3 phosphory-
lation (Figure 2D). This indicates that the same CD11b-positive
myeloid cells in the tumor thatmake IL-10 are responding to IL-10,
and that this signaling is distinct from the granulocyte popula-
tion. Our analyses of IL-10-stimulated ascites cells did not detect
any STAT3 phosphorylation in the CD45-negative fraction of the
ascites which includes the tumor cells (Figure 2E). These results
demonstrate that CD11b-positive immune cells distinct from the
Ly6G population in the tumor microenvironment selectively initi-
ate downstream signaling events in response to IL-10 stimulation,
that the MDSC population in the tumor is a speciﬁc mediator
of IL-10 signaling, and that IL-10 mediates its effects through
immune modulation rather than by direct effect on tumor cells.
IL-10 DICTATES THE IMMUNOSUPPRESSIVE PHENOTYPE OF MDSCs IN
THE TUMOR MICROENVIRONMENT
Since the tumor-inﬁltrating MDSCs are both the primary pro-
ducers and responders to IL-10, we hypothesized that this may
represent a novel autocrine or paracrine network by which MDSC
function is enabled and enforced. However, MDSCs are known to
produce a variety of immunosuppressive molecules and thus the
functional and potentially redundant role of IL-10 on these cells
is unknown. To test this, we returned to the chimeric mouse sys-
tem. We asked whether the congenic WT and IL-10R−/− MDSCs,
derived from the same tumor, only differing in their expression of
the IL-10R, exhibited phenotypic and functional differences. FACS
analysis showed an increased expression of MHC-II and CD86 on
both the CD11chi cells (Figure 3A) and the total CD11b+ cells
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FIGURE 1 | Leukocytes are the predominant cellular source of IL-10 in the
tumor microenvironment. (A) Supernatants from 106 ID8 tumor cells, or
CD11b+ MDSC cultured for 24 h were analyzed for IL-10 by ELISA. SD is
shown (n=5). (B) Naïve and tumor-bearing mice were analyzed for IL-10
reporter staining on CD11b+ myeloid cells (top panels, pre-gated on total live
cell forward and side scatter), and CD4+ or CD8+ leukocytes (bottom panels,
pre-gated for lymphocytes based on forward and side scatter) in the
peritoneum of naïve and tumor-bearing mice was assessed. Quantiﬁcation of
reporter mice analyses (C) and percentages of gated populations within the
ascites (D). (E) IL-10 reporter staining on GR-1+ cells in the peritoneum. (F)
Phenotypic analysis of Ly6C and Ly6G expression on cells from the ascites
pre-gated on CD11b. (G) Expression of F4/80 on the CD11b+ population in the
ascites. (H) Expression of CD11c on the CD11b+ population in the ascites. (I)
Percentage composition in the ascites of FOXP3T regulatory cells by
successive gating on CD45, CD4, and FOXP3-GFP, and MDSC gated on
CD115-GFP and CD11b staining in FOXP3/MAFIA mice. ND, not detected.
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(Figure 3B) from the IL-10R knockout compartment compared to
the congenic wild-type compartment in the ascites of these mice.
This is indicative that IL-10 is an important in vivo modulator
of myeloid maturation and activation in the tumor microenvi-
ronment. Importantly, we assessed the functional consequences
of IL-10 signaling on the myeloid populations in the tumor
FIGURE 2 | IL-10-elicited STAT3 signaling is preferentially induced in
tumor-associated leukocytes. (A) Mixed chimeric mice were generated
by reconstituting lethally irradiated wild-type mice with three million bone
marrow cells from both wild-type and IL-10R−/− mice. (B) Relative
chimerism of reconstituted mice shown by congenic marker staining. (C)
IL-10 responsive cells in the ascites of ovarian tumor-bearing mice were
identiﬁed by comparing phospho-STAT3 staining after a 10-min ex vivo
stimulation with IL-10 (100 ng/ml). Comparison of phospho-STAT3 staining
CD11b+ cells from congenic IL-10R deﬁcient (CD45.1+) and wild-type
(CD45.1−) cells isolated from the ascites of an IL-10R knockout and
wild-type mixed bone marrow chimeric mouse. (D)Western blot for
phospho-STAT3 from 106 unstimulated or IL-10 (10 ng/ml for 30min)
stimulated Ly6G bead-selected cells (pooled from the ascites of two mice),
and Ly6G-depleted CD11b+ cells from the same two mice; total STAT3 is
shown as a loading control. (E) CD45-negative cells are shown, with IL-10
treated (black dotted line) compared to untreated (gray) cells.
microenvironment by sorting wild-type and IL-10R knockout
CD11b+Ly6G− MO-MDSC populations, based on expression of
the CD45.1 congenic marker, from tumor-bearing chimeric mice
to test their suppressive capacity. The IL-10R−/− MDSCs were sig-
niﬁcantly impaired in their ability to suppress T cell activation, as
assessed by IFN-γ production, compared to the wild-type MDSCs
when titrated into a mixed splenocyte reaction (Figure 3C). To
determine if the decrease in suppressive capacity from the IL-
10R deﬁcient MDSC was dependent on IL-10 production by the
MDSC,we ﬁrst compared IL-10 production by sorted MDSC from
each genotype by ELISA and did not detect a signiﬁcant difference
(Figure 4A). Furthermore, IL-10 production by the MDSC does
not appear to be a direct means of suppression in our in vitro
FIGURE 3 | Acquisition of tumor phenotype in myeloid cells requires
the IL-10 receptor. Chimeric mice were injected with tumors and analyzed
for relative expression of MHC Class II and CD86 on tumor-associated (A)
CD11b+CD11c+ cells and (B) total CD11b+ cells, from either wild-type or
IL-10R−/− (identiﬁed by congenic CD45.1) background. (C)To assess the
suppressive capacity of the MDSC populations from each background,
CD11b+Ly6G− MDSCs were sorted and titrated into mixed splenocyte
reactions stimulated with anti-CD3 (1μg/ml). Interferon-γ secretion into the
supernatants was analyzed by ELISA. n=3 for all experiments, SD is
shown, statistical signiﬁcance (*p<0.05, **p<0.01) was determined by
Student’s t Test.
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suppression assay since blockade of IL-10R signaling by antibody
(Figure 4B) as well as the use of IL-10R knockout responder
splenocytes did not alleviate relative suppression (Figure 4C).
Therefore the IL-10 dependent differences in suppression from
the sorted chimeric MDSC are not reliant on differential IL-10
production. From this we propose that signaling through the IL-
10 receptor is a required component to establish the phenotypic
and functional characteristics of MDSC in tumor-bearing hosts,
and IL-10 is non-redundant in aspects of programming myeloid
populations within the tumor.
THERAPEUTIC BLOCKADE OF THE IL-10 RECEPTOR INHIBITS OVARIAN
TUMOR PROGRESSION
The critical role for IL-10 signaling to the MDSC tumor-
promoting phenotype and function led us to hypothesize that it
FIGURE 4 | In vitro suppression does not require IL-10 production by
MDSC. (A) IL-10 production from sorted WT and IL-10R−/− CD11b+Ly6G−
MDSC derived from chimeric mice was assessed by ELISA from 48-h
culture supernatants. To assess the requirement for IL-10 in the suppressive
capacity of MDSC, CD11b+Ly6G− MDSCs were (B) selected and added at
1:10 ratio with or without anti-IL-10R (100μg/ml), or (C) titrated as indicated
into mixed splenocyte reactions with either WT or IL-10R−/− splenocytes
stimulated with anti-CD3 (1μg/ml). Interferon-γ secretion into the
supernatants was analyzed by ELISA. n≥3 for (A,B) and n≥2 for (C), SD is
shown.
might be an efﬁcacious therapeutic target to inhibit tumor pro-
gression. We have previously shown that elimination of MDSCs
FIGURE 5 |Therapeutic blockade of the IL-10 receptor inhibits ovarian
tumor progression. (A) ID8 tumor-bearing mice received PBS, 100μg rat
IgG, or 100μg anti-IL-10 receptor antibody every third day for 2weeks
starting 2weeks post-ID8 injection. Mice were analyzed 2weeks later for
total cellularity (B), presence of the CD11b+CD11c+ MDSC in the
peritoneum (C), and for the presence of IL-10 (D,F), and IL-12p70 (E,G) in
the ascites (Luminex analysis); similar results were observed regardless of
whether the control injection was PBS (D,E) or non-speciﬁc IgG (F,G). (H)
Mice receiving 2weeks of either rat IgG or anti-IL-10 receptor antibody
starting 1week after ID8 injection. Statistical signiﬁcance (*p<0.05,
**p<0.01, ***p<0.0001) was determined by Student’s t Test for (B–D),
and by Kaplan–Meier analysis for survival (n≥8).
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in the ovarian tumor microenvironment reduces tumor progres-
sion and restores immune function (Bak et al., 2007), therefore
we hypothesized that IL-10 receptor blockade may provide an
alternative method to induce the therapeutic efﬁcacy observed
with MDSC depletion. To determine if IL-10 signaling block-
ade inhibited ID8 progression, we measured cellularity in the
tumor-associated ascites and, most importantly, survival. Mice
were injected with ID8 tumors and subsequently received ﬁve
intraperitoneal injections of anti-IL-10R antibody, spaced every
third day, starting 14 days post-tumor inoculation (Figure 5A).
At 1-week post-treatment, control mice had developed discern-
able ascites. However, compared to mice that received PBS or
IgG injections, treated mice had signiﬁcantly less total cellular-
ity (Figure 5B) and signiﬁcantly fewer MDSCs in the ascites
(Figure 5C). Additionally, cytokine analyses of the peritoneal
lavages indicate that IL-10 levels were reduced in the treated mice
(Figures 5D,F), which is in accord with the reduction in IL-10-
producing MDSCs within the peritoneum. Importantly, treated
mice had signiﬁcantly increased IL-12p70 levels, indicating an
important pro-inﬂammatory alteration in the peritoneum of the
treated mice (Figures 5E,G).
To determine if IL-10 receptor blockade provides a therapeu-
tic survival advantage in tumor-bearing mice, we used the same
injection strategy, instead starting 1-week post-tumor inoculation
(similar strategy as in Figure 5A). Mice that received the IL-10R
blocking therapy showed signiﬁcantly and substantially enhanced
survival over mice receiving injections of rat IgG control antibody
(Figure 5H). These data support a critical role for MDSC in tumor
progression and identify a crucial role for the MDSC-produced
IL-10 in the tumor microenvironment. Importantly, this is the
ﬁrst demonstration that IL-10 receptor blockade has therapeutic
efﬁcacy against an aggressive model of ovarian cancer.
We hypothesized that the MDSC reduction (Figure 5C) was
due either to antibody-mediated depletion of this cell population,
or a reduction in the recruitment of this population. Conﬁrm-
ing previous reports that the anti-IL-10R antibody is blocking
but non-depleting, naïve mice that received an i.p. injection of
100μg anti-IL-10R antibody had no measurable cellular depletion
(Figure 6); as a positive control, anti-CD8 depleted mice exhibited
a complete eradication of the CD8+ T cell population.
IL-10 SIGNALING MODULATES T CELL PHENOTYPES IN THE TUMOR
MICROENVIRONMENT
While it is known that theMDSCpopulation in the tumor can pro-
duce several immunosuppressive molecules that potentially alter
T cell activity, the direct effect(s) from the high levels of IL-10
present in the tumormicroenvironment onT cells is unknown and
cannot be ascertained from the previous anti-IL-10R experiments.
Two alternate, and not mutually exclusive possibilities include that
any differential in T cell anti-tumor function could be due to the
direct action of IL-10 on the T cells, or indirect effects on T cells
mediated through altered MDSC function.
We next determined if IL-10 in the tumor microenviron-
ment has a direct effect on inﬁltrating T cells or only affects
them by modulating MDSC function. We returned to the IL-10R
chimeric mice to evaluate differences between IL-10R knockout
andwild-typeT cells derived from the same tumor-bearingmouse.
Analogous to the methods used in Figure 3 to identify differential,
IL-10R-dependent, MDSC activity, we analyzed PD-1 and CD62L
levels on T cells from the ascites of chimeric tumor-bearing mice
as markers of activation status. In normal tumor-bearing mice,
T cells in the ascites are skewed CD62Llo (Figure 7A). While the
population of CD62Llo T cells in the wild-type mice might sug-
gest further differentiation and a more activated status, these cells
are clearly ineffective at responding to the tumor. In the ascites
of chimeric mice, the percent of CD62LloCD8+ T cells from
the IL-10R−/− cells, identiﬁed by expression of the CD45.1 con-
genic marker, was signiﬁcantly less than from the wild-type cells
(Figures 7B,C left). In contrast, the peritoneal CD8+ T cells from
naïve chimeric mice from both the wild-type and IL-10R knock-
out background were dominantly CD62Lhi, indicating that this
phenotype is speciﬁc to the tumor environment and is not inher-
ent in the IL-10R knockout T cells (Figure 7D). Similar trends
were observed in the CD4+ T cell pools of chimeras although the
differences in CD4 T cells expressing low levels of CD62L did not
reach signiﬁcance (Figures 7A,C,D right panels). Additionally, we
did not detect differences in PD-1 expression regardless of IL-
10R expression on CD8+ T cells in the ascites of tumor-bearing
chimeric mice (Figure 7E). To determine if IL-10 is sufﬁcient to
cause the down-regulation of CD62L in a puriﬁed system, we
selected CD8 T cells from the spleens of naïve IL-10R knockout
and wild-type mice, and found that 72-h IL-10 stimulation in vitro
was able to induce a modest down-regulation of CD62L surface
expression on the CD62L high cells from wild-type, but not IL-
10R knockout spleens (Figures 7F–H); the in vitro changes were
more modest than those in vivo (Figures 7A,B), which suggests
additional in vivo factors also inﬂuence this effect. Matsuzaki et al.
(2010) recently described a population of antigen speciﬁc tumor-
associated CD8+ T cells in human epithelial ovarian cancer, with
impaired effector functions, and showed that IL-10 was able to
induce the expression of the inhibitory marker LAG-3 on healthy
peripheral blood lymphocytes (PBL). We further characterized
the T cells in chimeric mice by analyzing LAG-3 and CD44 expres-
sion, and found the CD44+CD8+ population from the IL-10R−/−
background expressed signiﬁcantly less of the inhibitory marker
LAG-3 thanwild-type cells in the same tumor (Figures 8A,B). Fur-
thermore, upon gating on the CD44+CD62L populations of each
genotype (Figure 8C, Gate 1 and 2), we ﬁnd that LAG-3 expres-
sion on the CD62Llo cells (Figure 8C, right panels) was consistent
with the CD62Llo population we observed at an increased fre-
quency in the wild-type population in Figure 7C. Furthermore,
T cells from the IL-10R−/− background that expressed LAG-3
expressed it at lower levels by MFI (Figure 8C, gate 1). This indi-
cates that IL-10 signaling is required for normal generation of a
CD62LloLAG-3+CD8+CD44+ population in vivo at the tumor
site, and demonstrates that IL-10 signaling can directly inﬂuence
T cells by driving LAG-3 expression in the murine tumor. To
determine if LAG-3 expression correlates with functional differ-
ences from T cell populations, we comparatively assessed LAG-3-
expressing and -absent T cells from tumor-bearing chimeric mice
for IFN-γ production. We found that directly ex vivo, there are
no signiﬁcant differences in the frequency of IFN-γ producing
CD8 T cells from the LAG-3 positive and negative populations
from either IL-10R knockout cells or WT cells (Figure 8D left
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side), which may represent suppression enforced by other means
in the tumor. Following a 5-h anti-CD3 stimulation we did detect
signiﬁcantly more IFN-γ producing cells in the LAG-3 negative T
cells compared to the LAG-3 positive cells (Figure 8D right side).
While similar proportions of the wild-type and IL-10R knock-
out CD8 T cell populations were capable of producing IFN-γ,
the increased ability of the LAG-3 negative cells, which are more
prevalent in the IL-10R knockout compartment, indicates that IL-
10 drives the development of a LAG-3 expressing population of T
cells whose production of functional IFN-γ is impeded compared
to the LAG-3 negative cells.
THERAPEUTIC EFFICACY OF IL-10R BLOCKADE REQUIRES T CELLS
Our previous studies demonstrated systemic MDSC-mediated
suppression of T cells in sites distal to the tumor, including the
spleen (Peter et al., 2009). To ascertain if the IL-10R therapy
(Figure 5), which reduced the levels of MDSCs accumulating
within the tumor microenvironment, impacted the ability of T
FIGURE 6 |The anti-IL-10R antibody does not induce cellular depletion. Naïve mice were injected i.p. with 100 ng of either depleting anti-CD8 antibody,
anti-IL-10R antibody, or rat IgG control antibody. Mice were subsequently sacriﬁced and peritoneal lavages were collected, stained for CD45, CD8, CD11b, or
CD11c as indicated, and analyzed by FACS.
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cells to respond in these mice, we analyzed splenic CD8+ T cells
from mice treated with IL-10R antibody or PBS starting 2 weeks
post-tumor injection by stimulating ex vivo and analyzing for
intracellular IFN-γ production. Signiﬁcantly more CD8+ T cells
from the treated mice produced IFN-γ than the same cells in con-
trol IgG treated mice (Figure 9A). Therefore, even in mice treated
FIGURE 7 | IL-10 signaling modulatesT cell phenotypes in the ovarian
tumor microenvironment. (A)The CD62L status of peritoneal CD8+ and
CD4+ T cells from wild-type mice bearing ID8 tumors was analyzed (n=6).
Naïve [(B), left] and tumor-bearing [(B), right] mixed (IL-10R−/− and wild-type)
chimeric mice were analyzed for CD62L expression on IL-10R-deﬁcient
(CD45.1+) or -expressing (CD45.2+) congenically marked CD8T cells from the
peritoneum. (C)The percentages of CD8 (left) and CD4 (right) T cells
expressing low levels of CD62L from the wild-type or IL-10R−/− background
were quantiﬁed. (D) CD62Llo percentages of CD8+ (left) and CD4+ (right) T
cells from naïve chimeric mice from the wild-type and IL-10R knockout
compartments were assessed. (E) Additionally, CD8T cells from
tumor-bearing mixed chimeric mice were analyzed for the phenotypic marker
PD-1. (F) Relative CD62L status of WT and IL-10R−/− CD8T cells stimulated
with 10 ng/ml IL-10 for 72-h, assessed by FACS analyses (n≥3). (G)
Representative CD8 CD62L staining with gate for CD62Lhi population shown
in (H). (H) CD62L on IL-10-stimulated (black empty histogram) and
-unstimulated (gray ﬁlled histogram) CD8T cells. Statistical signiﬁcance
(*p<0.05, **p<0.01, ***p<0.0001) was determined by Student’s t Test.
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FIGURE 8 | CD8T cells require IL-10 signaling to obtain tumor-associated
LAG-3 expression levels. (A,B)The percentage of LAG-3+ cells from the
CD8+CD44+ tumor-associatedT cells of each background was analyzed.
(C) CD8+ tumor-associatedT cells in a chimeric mouse were analyzed
for CD44 and CD62L (left, wild-typeT cells shown). CD44 high cells
were gated as shown, and the LAG-3 expression on the CD62L hi (black
line) or lo (gray ﬁlled line) populations was determined for each
genotype (right panels). The LAG-3 MFI (geom. mean) with SD for
the respective CD62L hi and lo populations is shown. (D) Percentage
of IFN-γ producing cells in the CD8 population from WT or IL-10R−/−
backgrounds, gated on LAG-3 expression, unstimulated (left) or
stimulated for 5 h with 10μg/ml anti-CD3 (right; n=3). Statistical
signiﬁcance (*p<0.05, **p<0.01, ***p<0.0001) was determined by
Student’s t Test.
after 2 weeks of tumor progression, therapy was able to restore
systemic T cell function.
Since IL-10R blockade is able to reduce systemic suppression in
tumor-bearingmice, and the phenotypic changes onT cells seen in
the chimeric mice show direct IL-10 inﬂuence on T cells, we tested
the therapy on TCRα knockout mice, devoid of both CD4+ and
CD8+ T cells. The knockout mice received the same anti-IL-10R
treatment regimen as in Figure 5D starting 1 week after tumor
injection. The lack of T cells resulted in no signiﬁcant difference
in tumor growth or survival in the TCRα knockout mice regard-
less of whether they received the IL-10R therapy (Figure 9B). To
further clarify the requirement for T cells in the efﬁcacy of the IL-
10R therapy, we repeated the therapy in mice receiving concurrent
injections of CD8 depleting antibody (Figure 9C). Therapeutic
efﬁcacy is lost in mice without CD8 T cells, in demonstration of
a direct requirement for CD8 T cells in the efﬁcacy of the IL-
10 receptor blocking therapy. To further dissect the independent
effects of IL-10 modulation of MDSC accumulation and function
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FIGURE 9 |Therapeutic efficacy of IL-10R blockade requiresT cells. (A)
Splenic CD8+ T cells from treated mice (treatment scheme from Figure 4)
were analyzed by intracellular staining for IFN-γ production after anti-CD3
stimulation. (B)Tumor-bearing TCRα knockout mice were treated with
anti-IL-10R or, rat IgG 1week after tumor injection every other day for
2weeks and then survival was assessed. (C)Tumor-bearing WT mice, or
WT mice receiving weekly injections of CD8 depleting antibody, were
treated with anti-IL-10R or rat IgG 1week after tumor injection every other
day for 2weeks and then survival was assessed. (D) Mixed bone marrow
chimeric (IL-10R knockout: TCRα knockout, 20:80 respectively) mice were
treated with anti-IL-10R or rat IgG 1week after tumor injection every other
day for 2weeks and then survival was assessed. Statistical signiﬁcance
(*p<0.05) was determined by Student’s t Test and by Kaplan–Meier
analysis for survival. NS, not signiﬁcant.
from IL-10 alterations detected on T cells, we generated chimeric
mice reconstituted with an 20:80 ratio of bone marrow from
IL-10R knockout mice and TCRα knockout mice, respectively,
which yields mice that have both wild-type and IL-10R knock-
out MDSC, but all T cells are IL-10R deﬁcient. Survival studies of
these tumor-bearing mice indicate that loss of IL-10R on T cells
does not affect tumor growth or mouse survival since the tumors
in these mice progressed with expected kinetics (Figure 9D). The
ability of IL-10-ignorant T cells in these mice to confer survival
indicates that the functionality of the T cells in these mice is likely
being inhibited through additional mechanisms. Furthermore, the
anti-IL-10R therapy was still sufﬁcient to extend survival in these
mice (Figure 9D), indicating that the observed IL-10 effects on T
cells are secondary to the role of IL-10 in MDSC function. This
demonstrates that IL-10 can inﬂuence T cell phenotype and func-
tion through both IL-10-driven MDSC inhibition and direct IL-10
receptor ligation resulting in an ineffective T cell pool incapable
of responding to the tumor.
DISCUSSION
Myeloid-derived suppressor cells and the cytokine IL-10 are
emerging as key immunosuppressive mediators and enforcers
present in a myriad of cancers and in other chronic diseases. A
preponderance of data from a variety of systems now support that
both of thesemodulators are potently immunosuppressive in vitro,
and that their presence corresponds with tumor progression and
severity in vivo. Speciﬁcally, in bothmurinemodels of ovarian can-
cer and in the clinical disease the tumor recruits massive numbers
of immunosuppressive leukocytes into the peritoneal ascites, and
IL-10 levels correlate with clinical disease severity (Loercher et al.,
1999; Santin et al., 2001; Kryczek et al., 2006b; Mustea et al., 2009;
Nowak et al., 2010). Despite this, the precise contributions and
roles of MDSCs and IL-10 within the in vivo tumor microenvi-
ronment remain indistinct, in regard to IL-10 it is not clear if
there is functional redundancy with other immunosuppressive
molecules and, perhaps most importantly, the interrelationship
between the MDSC and IL-10 immunosuppressive networks and
mechanisms are unknown. Here we demonstrate that IL-10 pro-
duction by MDSCs, and MDSC responsiveness to IL-10, plays a
critical role in the failure of the immune system to control ovarian
tumor growth, resulting from a breakdown in multiple integral
components required for effective anti-tumor immunity.
It is well known that MDSC are involved in a plethora of dis-
eases and disease models including infection (Sander et al., 2010),
cancer (Marigo et al., 2008; Ostrand-Rosenberg and Sinha, 2009),
transplantation (Adeegbe et al., 2010; Highﬁll et al., 2010), and
autoimmunity (Yin et al., 2010), and are thought to provide spe-
ciﬁc inhibition of immune responses by renderingT cells impotent
through production of a number of inhibitory factors such as
iNOS, arginase, and peroxynitrites (Ochoa et al., 2007; Marigo
et al., 2008; Gabrilovich and Nagaraj, 2009). Less understood are
the speciﬁc signals required for the generation of MDSC, how-
ever some of the key factors in this process are now beginning
to be identiﬁed. IL-6, G-CSF, and GM-CSF have been used in
the in vitro generation of MDSC (Dolcetti et al., 2010; Lechner
et al., 2010) and additional factors that appear to be sufﬁcient to
regulate aspects of MDSC expansion and function include COX-
2, PGE, and VEGF (Marigo et al., 2008; Ribechini et al., 2010).
While some of these signals that are sufﬁcient to induce MDSC
phenotype and function have been identiﬁed, the signals that are
necessary for the in vivo generation of MDSC and, correspond-
ingly, those that could be used to inhibit MDSC generation or
function, are not at all clear. Previous in vitro experiments sup-
port that IL-10 is capable of modulating myeloid activation states,
and it has been hypothesized that IL-10 may play a regulatory
role in MDSC biology (Sinha et al., 2007; Ribechini et al., 2010),
however the speciﬁc requirements for IL-10 for in vivo MDSC
programming and function have not previously been explored.
Here we demonstrate that IL-10 is a requisite and direct func-
tional contributor that establishes the suppressive phenotype and
function of MDSCs. We have previously reported the presence of
a massive MDSC population in the ID8 ovarian cancer model
capable of suppressing in vitro T cell responses and that are
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required in vivo for normal tumor progression (Bak et al., 2007,
2008). With the use of chimeric mice that contain both IL-10-
responsive and -unresponsive MDSC, we now provide an in vivo
demonstration that loss of IL-10 signaling can singularly shape
the function of these MDSC and thereby functionally tilt the bal-
ance of the host environment in favor of tumor growth. This
experimental model represents the ﬁrst in vivo demonstration that
concurrent MDSC production of, and responsiveness to, IL-10 is
necessary for enforcement of immunosuppression by these cells
and elucidates a novel paracrine MDSC IL-10 signaling network
in ovarian cancer. We propose that the IL-10 pathway represents
a potentially efﬁcacious target in the diseases listed above where
MDSC related disease biology could be altered by modulation of
MDSC function.
To determine the therapeutic efﬁcacy of blockade of the tumor
IL-10 network, we used anti-IL-10 receptor antibody to block IL-
10 signaling during tumor progression. This was deemed prefer-
able to using IL-10 or IL-10 receptor knockoutmice since antibody
blockade is therapeutically relevant; and these knockout mice
have well-documented inherent inﬂammation (Kuhn et al., 1993;
Spencer et al., 1998). Mice treated i.p. with anti-IL-10R anti-
body show reduced tumor burden and peritoneal cellularity and,
most importantly, extended survival (Figure 5). Since our STAT3
phosphorylation analyses only detected CD45+ cells in the ascites
responding to IL-10 stimulation, we conclude that therapeutic
efﬁcacy lies in alleviation of suppression of the immune system
rather than a direct effect on tumor cell growth or survival. The
improved IFN-γ responsiveness from CD8+ splenic T cells in
treated mice led us to ask if IL-10 was mediating these effects
solely through amyeloid intermediary or if IL-10 could also induce
changes in T cells. The substantially altered CD62L and LAG-3
expression from IL-10R knockout T cells in the ascites of the IL-
10R chimeric mice provide formal evidence of IL-10-mediated
phenotypic changes on T cells in the ascites of tumor-bearing
mice. Recent reports suggest that CD62L-expressing T cells might
represent less differentiated early effectors with greater prolifera-
tion capacity and increased survival capabilities (Klebanoff et al.,
2005; Gattinoni et al., 2006; Diaz-Montero et al., 2008). Addition-
ally, reports indicate that skewing of CD62Llo expression corre-
spondswithMDSC levels, and is proposed to limit T cellmigration
into sites of tumor growth, thereby reducing T cell responsiveness
(Hanson et al., 2009). Based on the CD62L skewing on IL-10R−/−
T cells in chimeric mice, MDSC-produced IL-10 may represent a
potential mechanism for control of CD62L expression on T cells
and therefore the ability of T cells to mount an effective immune
response against the tumor. While data presented here indicates
that IL-10 signaling networks as a whole are crucial for the sys-
tematic inhibition of T cell responsiveness, and blockade of these
is sufﬁcient to restore T cell functionality, the individual contribu-
tion of IL-10 effects on myeloid activation versus direct effects on
T cells remains to be elucidated.
The highly immunosuppressive microenvironment established
by progressive ovarian tumors is an important and often
unaccounted-for obstacle to the success of many immunother-
apeutic strategies. Previous studies have shown that elimination
of suppressive, tumor-supporting leukocytes in the tumor can be
efﬁcacious (Bak et al., 2007; Huarte et al., 2008; Vincent et al.,
2010), however the identiﬁcation of selective pathways to neu-
tralize their suppressive capacity may provide quicker and more
speciﬁc therapies. Of direct relevance, studies taking advantage
of the phenotypic plasticity of myeloid cells by re-activating them
through TLR and CD40 (Scarlett et al., 2009), or block suppressive
mechanisms through phospho-diesterase-5 inhibition (Seraﬁni
et al., 2006) or triterpenoid (Nagaraj et al., 2010) have had con-
siderable success. Thus, the identiﬁcation of IL-10 as a master
regulator of the suppressive phenotype of the tumor is of crit-
ical importance. Notably, therapeutic IL-10 pathway inhibitors
have been developed and established as safe in clinical trials for
autoimmunity (Llorente et al., 2000). Data herein identify the
IL-10 pathway as a non-redundant network critical to ovarian
tumor-associated immunosuppression and, concomitantly, as a
therapeutic target that may enhance the efﬁcacy of current and
emergent immunotherapies.
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